Relmada Therapeutics to Present at Jefferies London Healthcare Conference

GlobeNewswireNov 19 22:00

Express News | Relmada Therapeutics Inc - Phase 2a Proof-of-Concept Study Expected to Begin in H1 2025

BreakingsNov 14 20:31

Express News | Relmada Therapeutics Initiates Phase 1 Dosing With Rel-P11 for Metabolic Disease

BreakingsNov 14 20:30

Relmada Therapeutics Initiates Phase 1 Dosing With REL-P11 for Metabolic Disease

GlobeNewswireNov 14 20:30

Relmada Therapeutics: Strong Buy on Promising Pipeline and Financial Stability

TipRanksNov 11 14:27

Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript Summary

Futu NewsNov 10 22:59 · Conference Call